Tango Therapeutics reports 92% objective response rate for vopimetostat combination in pancreatic cancer

Tango Therapeutics said initial Phase 1/2 data for its vopimetostat and daraxonrasib combination showed a 92% objective response rate in response-evaluable patients with previously treated MTAP-deleted pancreatic ductal adenocarcinoma, a difficult-to-treat form of pancreatic cancer.

The company said the result was based on 11 responses among 12 response-evaluable patients. Tango also reported a 90% six-month progression-free survival rate and a 100% disease control rate in that cohort.

What Tango reported

In its June 8 release, Tango said the combination was generally well tolerated and that it had not seen any new safety signals. The company said the early data support advancing vopimetostat plus daraxonrasib into Phase 3 development in first-line MTAP-deleted pancreatic cancer.

The announcement was published on Tango’s investor relations site and mirrored in an SEC exhibit the same day. A company homepage news listing also showed the release as current.

Why it matters

The data are early and come from a small, response-evaluable cohort, but the reported response rate is notable in pancreatic cancer, where treatment options remain limited. Tango’s statement suggests the company may move faster toward later-stage development if the program continues to hold up in follow-up data.

The company has not said when it will release the next data cut, whether it will share regulator feedback on the Phase 3 design, or whether additional independent conference materials will add detail.